MedTrace Logo

Simplified Monitoring Myanmar SM2 Study

NCT04113629 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-02-21

No results posted yet for this study

Summary

The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and virological monitoring.

Conditions

  • Hepatitis C
  • Liver Cirrhoses
  • Liver Inflammation
  • HIV Infections

Interventions

DEVICE

HCV point of care machine

Xpert HCV Assay performed on the GeneXpert point of care machine

Sponsors & Collaborators

  • University of Public Health, Myanmar

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2020-12-22
Completion
2020-12-22

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04113629 on ClinicalTrials.gov